Soft Tissue Sarcoma Clinical Trials

For more information please visit: http://clinicaltrials.gov/ct2/show/NCT00919269?term=COG+D9902&rank=2

People with soft tissue sarcoma are asked to participate in a research study being conducted by Northwell Health.

This is a multicenter, open-label, phase 1 study that is being done to test intratumoral injections of TTI-621 in patients that have relapsed and refractory percutaneously accessible solid tumors or mycosis fungoides. The study will be performed in two different parts: Dose Escalation and Dose Expansion. During the escalation part ...

Sarcomas comprise a heterogeneous group of uncommon solid tumors of mesenchymal origin, of which more than 50 subtypes have been defined. In 2015, approximately 11,930 people will be diagnosed with sarcoma, and 4,870 will die of the malignancy. The primary management for most localized sarcomas is surgical resection when feasible. ...

PRIMARY OBJCETIVES: I. Grade >= 2 radiation morbidity (subcutaneous tissue fibrosis, joint stiffness, or edema) at 2 years. SECONDARY OBJECTIVES: I. Evaluate local control, regional control, distant metastasis, progression free survival, and overall survival. II. Evaluate the functional outcomes as assessed using the musculoskeletal tumor rating scale (MSTS) and the ...

For that purpose, this project is composed of 3 stages: A Calibration stage that will allow to evaluate the correlation between the clinical tumor response parameters (i.e. TV/AP features) and the radiobiological parameters issued from the A/MS bioassays in order to develop a mathematic model defining the UTCR parameter A ...

Aims The investigators plan a 2 year pilot observational study to: Identify and quantify circulating cell-fee DNA (cfDNA) in cases of Soft Tissue Sarcoma (STS) Investigate Telomere Maintenance Mechanisms (TMM) in STSs. Use TMM associated genetic mutations to identify and quantify tumour-derived cfDNA in STSs at time of tumour resection ...

PRIMARY OBJECTIVES: I. To evaluate whether symptom management and communication are improved in patients who are chemotherapy naive who receive a Sarcoma Treatment Guide as compared to those that have not. SECONDARY OBJECTIVES: I. To explore whether patients who have previously undergone chemotherapy benefit from a Sarcoma Treatment Guide (STG) ...

This is an open-label phase II study of TAK-228 for patients 18 years of age with complex genomic sarcomas exhibiting Phosphoinositide-3 Kinase (PI3K) pathway dysregulation. Patients must have surgically unresectable or metastatic disease that is refractory to at least one prior line of therapy (not including neoadjuvant or adjuvant therapy ...

Whole body (WB) and primary tumor diffusion weighted imaging (DWI) will be performed at baseline in all subjects. Additional DW-MRIs will be done up to 3 times during treatment at the same time as routine MRI examinations are scheduled. Follow-up primary tumor DWI MRI examinations will be performed at time ...